Eugenia punicifolia (Kunth) DC. as an adjuvant treatment for type-2 diabetes mellitus: A non-controlled, pilot study

Phytotherapy Research

Volumn 28, Issue 12, 2014, Pages 1816-1821

  Sales, Débora Simone ^a   Carmona, Fabio ^a   De Azevedo, Bruna Cestari ^b   Taleb Contini, Silvia Helena ^b   Bartolomeu, Ana Carolina Duó ^b   Honorato, Fernando B ^a   Martinez, Edson Z ^a   Pereira, Ana Maria Soares ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF RIBEIRÃO PRETO   (Brazil)

Author keywords

Herbal medicine; Hypoglycemic agents; Myrtaceae; Phytotherapeutics

Indexed keywords

C REACTIVE PROTEIN; CARYOPHYLLENE; ESSENTIAL OIL; EUGENIA PUNICIFOLIA EXTRACT; GALLIC ACID; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HERBACEOUS AGENT; HYPERIN; INSULIN; KAEMPFEROL 3 O RHAMNOSIDE; METFORMIN; MYRICETIN 3 O RHAMNOSIDE; PHYTOL; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; QUERCETIN 3 O XYLOSIDE; QUERCITRIN; REPAGLINIDE; THYROTROPIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG CAPSULE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG ISOLATION; EUGENIA PUNICIFOLIA; EVENING DOSAGE; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; INTERVENTION STUDY; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MORNING DOSAGE; MYRTACEAE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PLANT LEAF; POWDER; SYSTOLIC BLOOD PRESSURE;

MYRTACEAE;

EID: 84916227402     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5206     Document Type: Article

References (30)

1. Adams RP. 1995. Identification of Essential Oil Components by Gas Chromatography Mass Spectroscopy. Allured Publishing Corporation: Illinois.
2. American Diabetes Association. 2009. Standards of medical care in diabetes-2009. Diabetes Care 32(Suppl 1):S13-S61.
3. Blonde L. 2009. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve Clin J Med 76(Suppl 5):S4-S11.
4. Blonde L. 2010. Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. Am J Med 123 (3 Suppl):S12-S18.
5. Brunetti IL, Vendramini RC, et al. 2006. Effects and toxicity of Eugenia punicifolia extracts in streptozotocin-diabetic rats. Pharm Biol 44(1):35-43.
6. Choi JS, Yokozawa T, Oura H. 1991. Improvement of hyperglycemia and hyperlipemia in streptozotocin-diabetic rats by a methanolic extract of Prunus davidiana stems and its main component, prunin. Planta Med 57(3):208-211.
7. Dans AM, Villarruz MV, et al. 2007. The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. J Clin Epidemiol 60(6):554-559.
8. Elmazar MM, El-Abhar HS, et al. 2013. Phytol/phytanic acid and insulin resistance: potential role of phytanic acid proven by docking simulation and modulation of biochemical alterations. PLoS One 8(1):e45638.
9. Fernandes ES, Passos GF, et al. 2007. Anti-inflammatory effects of compounds alpha-humulene and (-)-trans-caryophyllene isolated from the essential oil of Cordia verbenacea. Eur J Pharmacol 569(3):228-236.
10. Ferreres F, Gil-Izquierdo A, et al. 2012. Bauhinia forficata link authenticity using flavonoids profile: relation with their biological properties. Food Chem 134(2):894-904.
11. Forbes JM, Cooper ME. 2013. Mechanisms of diabetic complications. Physiol Rev 93(1):137-188.
12. Galeno DM, Carvalho RP, et al. 2013. Extract from Eugenia punicifolia is an antioxidant and inhibits enzymes related tometabolic syndrome. Appl Biochem Biotechnol 172(1):311-324.
13. Grangeiro MS, Calheiros-Lima AP, et al. 2006. Pharmacological effects of Eugenia punicifolia (myrtaceae) in cholinergic nicotinic neurotransmission. J Ethnopharmacol 108(1):26-30.
14. Hui H, Tang G, Go VL. 2009. Hypoglycemic herbs and their action mechanisms. Chin Med 4(1):11.
15. Kamalakkannan N, Prince PS. 2006. Antihyperglycaemic and antioxidant effect of rutin, a polyphenolic flavonoid, in streptozotocin-induced diabetic Wistar rats. Basic Clin Pharmacol Toxicol 98(1):97-103.
16. Kuritzky L. 2010. Managing type 2 diabetes in the primary care setting: beyond glucocentricity. Am J Med Sci. 340(2):133-143.
17. Latha RC, Daisy P. 2011. Insulin-secretagogue, antihyperlipidemic and other protective effects of gallic acid isolated from Terminalia bellerica Roxb. in streptozotocin-induced diabetic rats. Chem Biol Interact 189(1-2):112-118.
18. Leite PE, De Almeida KB, et al. 2010. Anti-inflammatory activity of Eugenia punicifolia extract on muscular lesion of mdx dystrophic mice. J Cell Biochem 111(6):1652-1660.
19. Matsuda H, Nishida N, et al. 2002. Antidiabetic principles of natural medicines. V. Aldose reductase inhibitors from Myrcia multiflora DC. (2): Structures of myrciacitrins III, IV, and V. Chem Pharm Bull (Tokyo) 50(3):429-431.
20. Negri G. 2005. Diabetes melito: plantas e princípios ativos naturais hipoglicemiantes. Braz J Pharm Sci 41(2):121-142.
21. Punithavathi VR, Prince PS, et al. 2011. Antihyperglycaemic, antilipid peroxidative and antioxidant effects of gallic acid on streptozotocin induced diabetic Wistar rats. Eur J Pharmacol 650(1):465-471.
22. Rao MU, Sreenivasulu M, et al. 2010. Herbal medicines for diabetes mellitus: a review. Int J Pharm Tech Res 2(3):1883-1892.
23. Ruhe RC, McDonald RB. 2001. Use of antioxidant nutrients in the prevention and treatment of type 2 diabetes. J Am Coll Nutr 20(5 Suppl):363S-369S; discussion 381S-383S.
24. Salgueiro AC, Leal CQ, et al. 2013. The influence of Bauhinia forficata Link subsp. pruinosa tea on lipid peroxidation and non-protein SH groups in human erythrocytes exposed to high glucose concentrations. J Ethnopharmacol 148(1):81-87.
25. Santos CCdMP, Salvadori MS, et al. 2013. Antinociceptive and antioxidant activities of phytol in vivo and in vitro models. Neuroscience J 2013:1-9.
26. Shichiri M, Kishikawa H, et al. 2000. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23(Suppl 2):B21-B29.
27. Stratton IM, Adler AI, et al. 2000. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321(7258):405-412.
28. Tabas I, Glass CK. 2013. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339(6116):166-172.
29. WHO. 2006. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva, WHO Document Production Services: 50.
30. Yeh G, Eisenberg D, et al. 2003. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 26(4):1277-1294.